Clinical DevelopmentLast reviewed April 2026

IND-Enabling Studies(IND-Enabling)

The nonclinical studies a sponsor conducts to support the safety and feasibility of initiating human clinical trials under an IND.

Usage Examples

The IND-enabling package included 28-day GLP rat and dog tox supporting a 14-day Phase 1 dosing period.
Safety pharmacology studies were conducted per ICH S7A core battery.
Reproductive toxicology was deferred until before Phase 2 per ICH M3(R2).

What is IND-Enabling?

IND-enabling studies are the nonclinical package a sponsor must complete to justify initiation of first-in-human clinical trials. The FDA requirements are set out in 21 CFR 312.23 and elaborated in ICH M3(R2) guidance on nonclinical safety studies. The package typically includes toxicology studies (acute, repeat-dose, genotoxicity, reproductive, carcinogenicity where applicable), pharmacology (primary and secondary), safety pharmacology, ADME (absorption, distribution, metabolism, excretion), and manufacturing and analytical characterization.

Duration of repeat-dose toxicology must align with or exceed the duration of the proposed clinical trial. For a typical Phase 1 single-ascending-dose study, 14-day or 28-day GLP tox studies in two species (one rodent, one non-rodent) are typical. Longer clinical trials require longer nonclinical safety studies. Certain biologics with species-specific pharmacology may use relevant species alternatives.

The IND-enabling package is the core content of Module 4 (Nonclinical) in the CTD-formatted IND submission, and it forms the scientific foundation for First-in-Human dose selection, monitoring strategy, and stopping rules. Weaknesses in the nonclinical package frequently cause clinical hold orders when the IND is filed.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 312 23, ICH M3.

FDAEMAPMDA

When This Matters

The IND-enabling package included 28-day GLP rat and dog tox supporting a 14-day Phase 1 dosing period.
Safety pharmacology studies were conducted per ICH S7A core battery.
Reproductive toxicology was deferred until before Phase 2 per ICH M3(R2).

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

21 CFR 312 23ICH M3

Frequently Asked Questions

Per ICH M3(R2): acute and repeat-dose toxicology (duration ≥ planned clinical trial), genotoxicity screens, safety pharmacology (cardiovascular, CNS, respiratory), and ADME. Specific requirements vary by dose, duration, and indication. Reproductive toxicology can typically be deferred until Phase 2 for most programs.

Pivotal safety studies supporting the IND must be conducted under Good Laboratory Practice (21 CFR Part 58). Exploratory and mechanistic studies may be non-GLP. FDA expects the GLP vs non-GLP distinction to be clearly documented in the IND.

A typical first-IND-enabling package takes 12-18 months of dedicated nonclinical work. Timeline drivers include species selection, repeat-dose tox duration, analytical method development for bioanalysis, and manufacturing readiness for GLP drug substance production. Compressed timelines are possible but expensive.